Zolbetuximab is an antibody that specifically targets the claudin 18.2. Around one in three patients have high levels of claudin 18.2 in their gastric cancer, ...

The string of recent clinical successes for the antibody zolbetuximab has not only been welcome good news at AstraZeneca and Astellas, it has also buoyed biotechs working on their own Claudin ...

Zolbetuximab is a monoclonal antibody that targets CLDN18.2, a protein that serves as a biomarker in gastric and gastroesophageal junction cancers. If the FDA approved this novel drug, it would be the ...

Vyloy is a claudin 18.2-directed cytolytic antibody. The FDA has approved Vyloy (zolbetuximab-clzb) for the treatment of advanced gastric and gastroesophageal junction cancer.

Zolbetuximab is the first claudin 18.2–targeting agent approved in the United States. Approval of the monoclonal antibody was originally scheduled for earlier in the year but was delayed due ...

Zolbetuximab is a chimeric IgG1 monoclonal antibody that binds to CLDN18.2 on the cancer cell surface of gastric epithelial cells. This action results in antibody-dependent cellular cytotoxicity ...

The FDA approved zolbetuximab (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, in combination with chemotherapy for the first-line treatment of adults with advanced HER2-negative ...

Zolbetuximab is an antibody that specifically targets the claudin 18.2. Around one in three patients have high levels of claudin 18.2 in their gastric cancer, ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Commission (EC) has approved VYLOY™ (zolbetuximab) in combination with ...

Zolbetuximab, a first-in-class claudin (CLDN) 18.2-targeted monoclonal antibody, is recommended in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line tre ...